Translational scientist Jacqueline Achkar of Albert Einstein Medical College will lead several collaborations to build a point-of-care diagnostic platform.
The firm will develop a platform to detect toxic algal blooms in freshwater and marine environments using its Array System and LightDeck technology.
The assay captures modification states with antibodies targeting histone modifications while single-molecule sequencing reveals the genomic location.
The company will use the funding to prepare for the 2017 launch of its DiagCore integrated molecular and immunoassay near-patient testing platform.
Using Myriad RBM's platform, Mayo researchers identify proteins that could be markers of bipolar I depression.
Researchers hope to advance the technology to support an assay to help personalize oral cancer treatment by avoiding the development of mucositis.
Leveraging Quanterix's Simoa technology, PBL will be able to enter new markets and strengthen its current product offerings.
The approach could allow the use of antibody array tests in resource-poor areas where fluorescence detection systems are too expensive or difficult to maintain.
The firm will use the new funds to advance development of its lead product for the early diagnosis of prostate cancer.
Quanterix and BioMérieux recently announced a partnership giving BioMérieux worldwide exclusive rights to Quanterix's Single Molecule Array, or SiMoA, technology for clinical assay development and industrial applications.
Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.
In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.
The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.